Inhibition of complement in Guillain-Barré Syndrome: the ICA-GBS study by Davidson, Amy I. et al.
  
 
 
 
 
Davidson, A. I., Halstead, S. K., Goodfellow, J. A., Chavada, G., 
Mallik, A., Overell, J., Lunn, M. P., McConnachie, A., van Doorn, P. 
and Willison, H. J. (2017) Inhibition of complement in Guillain-Barré 
Syndrome: the ICA-GBS study. Journal of the Peripheral Nervous 
System, 6, pp. 4-12. (doi:10.1111/jns.12194) 
   
There may be differences between this version and the published 
version. You are advised to consult the publisher’s version if you wish 
to cite from it. 
 
This is the peer-reviewed version of the following article: Davidson, A. 
I., Halstead, S. K., Goodfellow, J. A., Chavada, G., Mallik, A., Overell, 
J., Lunn, M. P., McConnachie, A., van Doorn, P. and Willison, H. J. 
(2017) Inhibition of complement in Guillain-Barré Syndrome: the ICA-
GBS study. Journal of the Peripheral Nervous System, 6, pp. 4-12, 
which has been published in final form at 10.1111/jns.12194. This 
article may be used for non-commercial purposes in accordance 
with Wiley Terms and Conditions for Self-Archiving. 
 
 
 
http://eprints.gla.ac.uk/131370/ 
     
 
 
 
 
 
 
Deposited on: 19 December 2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
A
cc
ep
te
d 
A
rti
cl
e
This article is protected by copyright. All rights reserved. 
Inhibition of Complement in Guillain-Barré Syndrome: The ICA-GBS 
Study 
 
Amy I Davidson1,2, Susan K Halstead1, John A Goodfellow 1,2, Govind Chavada2, Arup 
Mallik3, James Overell2, Michael P Lunn4, Alex McConnachie5, Pieter van Doorn6, Hugh 
J Willison1,2. 
1. Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary 
and Life Sciences, University of Glasgow 
 
2. Department of Neurology, Institute of Neurological Sciences, Southern General 
Hospital, 1345 Govan Road, Glasgow 
 
3. Department of Clinical Neurophysiology, Institute of Neurological Sciences, 
Southern General Hospital, 1345 Govan Road, Glasgow 
 
4. Department of Neurology, National Hospital for Neurology and Neurosurgery, 
Queen Square, London 
 
5. Robertson Centre for Biostatistics, Boyd Orr Building, University of Glasgow. 
 
6. Department of Neurology, Erasmus MC, Rotterdam 
 
Corresponding author: 
Hugh J Willison 
Glasgow Biomedical Research Centre, Room B330, 
120 University Avenue, Glasgow G12 8TA, Scotland, UK. 
Tel:  44 141 330 8287; Fax: 44 141 330 4600;  
email: Hugh.Willison@glasgow.ac.uk 
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which 
may lead to differences between this version and the Version of Record. Please cite this 
article as doi: 10.1111/jns.12194
  
A
cc
ep
te
d 
A
rti
cl
e
This article is protected by copyright. All rights reserved. 
Abstract 
The outcome of Guillain-Barré syndrome remains unchanged since plasma exchange 
and intravenous immunoglobulin were introduced over 20 years ago. Pathogenesis 
studies on GBS have identified the terminal component of complement cascade as a 
key disease mediator and therapeutic target. We report the first use of terminal 
complement pathway inhibition with eculizumab in humans with GBS. In a randomised, 
double-blind, placebo-controlled trial, 28 subjects eligible on the basis of GBS disability 
grade of at least 3 were screened, of whom 8 (29%) were randomised. Five received 
eculizumab for four weeks, alongside standard intravenous immunoglobulin treatment. 
The safety outcomes, monitored via adverse events capture, showed eculizumab to be 
well tolerated and safe when administered in conjunction with IVIg. Primary and 
secondary efficacy outcomes in the form of GBS disability scores, MRC sum scores, 
Rasch Overall Disability Scores and Overall Neuropathy Limitation Scores are reported 
descriptively. For the primary efficacy outcome at 4 weeks after recruitment, 2 of 2 
placebo and 2 of 5 eculizumab-treated subjects had improved by 1 or more grades on 
the GBS disability score. Although the small sample size precludes a statistically 
meaningful analysis, these pilot data indicate further studies on complement inhibition in 
GBS are warranted. 
 
Key words: Guillain-Barré syndrome, complement, membrane attack complex, 
intravenous immunoglobulin, clinical trial, therapy, eculizumab. 
A
cc
ep
te
d 
A
rti
cl
e
This article is protected by copyright. All rights reserved. 
Introduction 
Over 20 years after their introduction, intravenous immunoglobulin (IVIg) and plasma 
exchange remain the only proven therapies for Guillain-Barré syndrome (GBS) (Hughes 
et al., 2014). Since the use of these interventions became routine in clinical practice, no 
further immunomodulatory therapies have been shown to significantly ameliorate the 
clinical course of GBS, whether used alone or in conjunction with IVIg (Hughes et al., 
2013). 
IgG anti-ganglioside antibodies are strongly implicated in the pathogenesis of at 
least some forms of GBS (Willison 2005; Willison et al., 1999) by activating complement 
during the acute inflammatory phase. Human biopsies from GBS subjects reveal 
complement deposits in nerves (Griffin et al., 1996). Data from animal models has 
demonstrated that inhibition of the terminal components of the complement cascade 
can abrogate nerve damage (Goodyear et al., 1999; Greenshields et al., 2009; Halstead 
et al., 2008; O'Hanlon et al., 2003; van Schaik et al., 1995; Yuki et al., 2001) thus 
making complement an attractive therapeutic target. 
Eculizumab (Soliris™) is currently the only commercially available complement 
C5 inhibitor approved for use in man. It is a humanised anti-C5 neutralising antibody 
which prevents the formation of MAC (Rother et al., 2007). In 2011, an open label 
clinical trial of eculizumab in multifocal motor neuropathy (MMN) provided valuable data 
on serum eculizumab concentrations required to inhibit MAC formation in subjects 
receiving concomitant IVIg (Fitzpatrick et al., 2011). We report here an exploratory study 
of eculizumab used as an add-on to IVIg in GBS. 
 
A
cc
ep
te
d 
A
rti
cl
e
This article is protected by copyright. All rights reserved. 
Materials and Methods 
 
Patients 
Patients that fulfilled the NINDS criteria for diagnosis of GBS (Asbury and Cornblath 
1990) were included. Entry criteria required participants to be at least 18 years of age, 
within 2 weeks of GBS symptom onset, have a GBS disability score (GBS DS) of at 
least 3 (defined as inability to walk 10m unaided), with no confounding medical 
conditions. Full inclusion and exclusion criteria are documented in Table 1. Regional 
ethical approval was given for the trial protocol and supporting documentation 
(REC13/SS/0117). All trial conduct was in keeping with the Declaration of Helsinki. The 
trial is registered on EudraCT database (unique no. 2013-000228-33) and 
Clinicaltrials.gov (NCT02029378). The trial was investigator-led, co-sponsored by the 
University of Glasgow and NHS Greater Glasgow and funded by Alexion 
Pharmaceuticals, Cheshire, Connecticut, USA. 
 
Study design 
Inhibition of Complement in Guillain Barré Syndrome (ICA-GBS) was designed as a 
phase 2, single centre, 2:1 randomised, double-blind, placebo-control trial aiming to 
recruit 30 patients over a 2 year period (August 2014 –  July 2016) with severe GBS. 
Randomisation and concealed allocation were performed by computer and an 
interactive web response system. In both arms, participants received IVIg at 2g/kg 
(0.4g/kg/day for 5 days). All participants were enrolled for a 6 month period, comprising 
8 visits, at weeks 0, 1, 2, 3, 4, 8, 13 and 26. Active drug (eculizumab, 900mg) or 
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placebo was given weekly (weeks 1, 2, 3 and 4) for the first 4 weeks. Concomitant 
antibiotics (Ciprofloxacin 400mg oral/500mg IV once weekly) were given to all 
participants for the first 10 weeks for meningococcal prophylaxis in the absence of an 
opportunity to vaccinate eculizumab recipients. When the first dose of study drug was 
administered, all participants were also receiving IVIg therapy (2g/kg in 5 divided doses 
over 5 days) at various timepoints. Outcome data, as denoted in Table 2, were collected 
throughout the trial and comprised GBS DS (Hughes et al., 1978) and MRC sum score 
(MRC SS) (Kleyweg et al., 1991) and both collected weekly. The R-ODS (van Nes et 
al., 2011) and ONLS (Draak et al., 2014) were collected at baseline, weeks 4, 8, 13 and 
26 visits (Table 2). For full descriptions of scales and scores, see Appendix 3A-D. 
 
Study outcomes 
The primary safety endpoint was the incidence of adverse events (AE) and serious 
adverse events (SAE) after treatment with eculizumab and IVIg compared to placebo 
controls who received IVIg only. Safety was recorded via AE and SAE reporting 
occurring during the treatment period and for unresolved SAEs the subsequent 6 
months. The primary efficacy endpoint was defined as improvement by one or more 
grades in GBS DS at 4 weeks. The secondary endpoints are documented in Table 2.  
 
Electrophysiology 
Routine clinical electrophysiological data were collected, with all subjects having a least 
one detailed study, recording from at least four nerve and muscle groups. These data 
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were then analysed by one clinical neurophysiologist (AM) and compared to the 
Rajabally diagnostic criteria (Rajabally et al., 2015). 
 
Laboratory and Pharmacological monitoring 
Blood samples were taken prior to each eculizumab or placebo dose, and assays were 
performed at baseline for anti-ganglioside antibodies by enzyme-linked immunosorbent 
assay (ELISA) (Willison et al., 1999) and microarray (Cao-Lormeau et al., 2016). 
 
Statistics 
The study protocol specified that a statistical analysis plan (SAP) would be formulated 
prior to unblinding the trial. Since the study only recruited 8 participants of the intended 
30, it was agreed that there would be no value to estimate treatment effect difference, 
and the final SAP consisted of descriptive analyses only. 
 
Results 
 
Subjects 
There were an unexpectedly large number of exclusions of potentially eligible subjects 
at pre-screening. Thus of the 28 subjects with severe GBS over the 2 year study period 
who underwent pre-screening, 20 subjects failed to enter the trial for a number of 
reasons (Figure 1, Appendix Table 1). Twelve of these subjects declined to participate, 
the most common reason being concern about the perceived risks of meningitis and 
infection associated with the trial drug. Eight were excluded for other reasons including 
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concomitant pyrexial illness, past history of meningococcal CNS infection, and inability 
to comply with study schedules. Table 3 lists baseline clinical characteristics of recruited 
subjects. 
 
Eight subjects were recruited and randomised. One randomised patient was withdrawn 
due to an exclusion criterion (incidental chest neoplasm identified on CT scanning) 
arising after consent was given, but before any baseline visit actions were undertaken. 
All 7 remaining subjects received standard IVIg treatment at 0.4g/kg per day for 5 days, 
with the first trial visit and dosing occurring during this time period. Of the 7 who 
received trial infusions and completed the study, 5 received eculizumab (subjects E1-
E5) and 2 received placebo (subjects P1-P2). One patient (E3), who was gradually 
improving from their GBS disability over the course of the study, died suddenly of septic 
shock at week 21. All other subjects (n = 6) completed the predefined 26 week 
observation period and outcome measures. 
 
All 7 subjects who completed the trial had clinical features that were typical for GBS with 
largely symmetrical motor weakness, reflex loss and elevated cerebrospinal fluid (CSF) 
protein. Five subjects had associated anti-ganglioside antibodies (Table 3). 
Electrophysiological studies (Appendix 4) showed that amongst the eculizumab-treated 
subjects, 2 (E1,E2) had AMAN/AMSAN pattern and 2 had AIDP patterns. One subject 
(E5) had equivocal studies. Both placebo patients had AIDP electrophysiological 
patterns. 
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Primary outcome – safety and tolerability 
Administration of the first dose of study drug occurred at least one hour post IVIg 
infusion. One patient reported a rash after the third dose of study drug; otherwise no 
infusion reactions were noted. Of the 5 who received eculizumab, 2 did not fully 
complete the 4 scheduled infusions. One patient (E3) received 2 out of 4 intended 
doses (missing weekly dose 3 and 4) and the other patient (E4) received 3 out of 4 
(missing weekly dose 3). In both subjects, treatment was withheld because of active 
respiratory infection with pyrexia and sepsis as per protocol. 
 
Adverse Events 
Adverse events were captured for the duration of the trial (Table 4 and Appendix Table 
2). For all 7 subjects who completed the full treatment phase of the trial, 29 AEs were 
reported. Twenty five were in the eculizumab arm and four in the placebo arm. The 2 
most commonly reported AEs, occurring in either group, were derangements in liver 
function (rising liver transaminases) and infections. In the 5 reported cases of liver 
function derangement, 3 subjects had mildly deranged transaminases prior to infusion 
of trial medications. All liver function test derangements had resolved by the end of the 
trial visits. Of those with an infectious AE, four had lower respiratory tract infections and 
one had acute cholecystitis. 
Four SAEs occurred in the eculizumab cohort and none in the control cohort.  Three 
were deemed as having no causality to the drug intervention and one with possible 
causality to the drug intervention. Subject E3 had a lower respiratory tract infection 
preventing administration of trial drug (possible causality), and died at week 21 due to 
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septic shock and multi-organ failure (non-causal). Subject E4 had opioid toxicity 
requiring high dependency unit admission (non-causal) and resulting in an aspiration 
pneumonia leading to intensive care unit admission (non-causal).  
 
Primary efficacy endpoint 
By 4 weeks, 2 of 2 placebo and 2 of 5 eculizumab-treated subjects had improved by 1 
or more grades on the GBS DS (Figure 2A, Table 4). 
 
Secondary Outcome Measurements 
 
Time to improvement of one GBS DS point  
Of the 5 who received eculizumab, 3 (E1, E2, E5, 60%) achieved an improvement of 1 
GBS DS grade over the duration of the trial (Figure 2A). This was achieved by week 2 
(E1), week 3 (E2), and week 13 (E5). The placebo-treated subjects achieved 
improvements of 1 GBS DS grade by week 1 (P1) and week 2 (P2) (Table 4, Figure 2).  
One of 5 eculizumab-treated subjects (E2) and 1 of the 2 placebo-treated subjects (P1) 
achieved a GBS DS score of 2 or less (independently walking) by week 8 of the trial. By 
week 13, 1 further eculizumab-treated patient (E1) and 1 further placebo-treated patient 
had also reached this outcome. Three of five eculizumab-treated subjects failed to 
achieve independent walking (GBS DS 2) by 6 months. One eculizumab-treated patient 
(E3) died of sepsis whilst still being ventilated at week 21. During the period prior to his 
death, motor function had been improving, as reflected in other scoring scales (E3 data 
from week 13 is displayed). 
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Rasch-built Overall Disability Score (R-ODS) 
At week 4, 2 of 5 (40%) eculizumab-treated subjects (E1 and E2) had an increase of at 
least 6 points on the R-ODS (with an 11 point and 38 point improvement respectively), 
whilst one further patient (E5) had an improvement of 5 points (Figure 2B). Both of the 
remaining subjects were very severely affected. One remained static with a R-ODS 
score of 0 (E3) and one deteriorated by 11 points (falling from 11 to 0; E4). Both 
placebo-treated subjects had achieved at least 6 point improvement at week 4, having 
improved by 41(E1) and 15 (E2) points. At week 26, 4 of 5 eculizumab-treated subjects 
had improved by at least 6 points (range from 16 to 74 points), as had both placebo-
treated subjects, achieving a 94 point (P1) and 64 point (P2) improvement. 
 
MRC sum score (MRC SS) 
At week 4, 2 eculizumab-treated subjects (E3, E4) had regressed in their MRC SS 
(Figure 2C). All other subjects (3 treated and 2 placebo) improved by at least one point. 
At week 26, 4 eculizumab-treated pateints had improved to near normal (range 54-59). 
At week 13, the MRC SS of E3 was 26. At 26 weeks, the 2 placebo-treated subjects 
had recovered (P1, 60; P2, 58). 
 
Overall Neuropathy Limitation Score (ONLS)  
Of the 5 eculizumab-treated subjects, 2 subjects (E1 and E2) had an improvement of at 
least 1 point (3- and 8-point improvement respectively) at 4 weeks (Figure 2D). Four 
eculizumab-treated subjects had an improvement of at least 1 point by week 26 (range 
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from 1 to 10 points). Patient E3 had improved by 1 point at week 13, and died at week 
21. Both placebo subjects had improved by 1 point at week 4, with an overall 
improvement of 7 (P1) and 10 (P2) ONLS points by trial completion. 
 
Ventilation requirements and Intensive Care Unit Admissions 
Three eculizumab-treated subjects required intensive care unit (ICU) admission, with 2 
eculizumab-treated subjects (E3 and E4) requiring mechanical ventilation (Table 4). 
Subject E3 had a progressive bulbar palsy and was electively intubated for airway 
protection before receiving eculizumab doses, and subject E4 required mechanical 
ventilation due to pneumonia and sepsis during week 2 and 3 of their admission after 
starting eculizumab doses. Patient E3 was ventilator dependent throughout the trial. 
Patient 4 was ventilated for 10 days, though due to bulbar weakness retained a 
tracheostomy for 5 months. Patient E2 required high dependency care with high flow 
oxygen and non-invasive ventilation for 5 days, but did not require invasive mechanical 
ventilation. Neither placebo-treated subjects required ICU level care. 
 
Two eculizumab-treated subjects required inotropic support for unstable blood pressure.  
Patient E3 had a combination of autonomic dysfunction secondary to GBS and sepsis, 
and required inotropic support for 6 weeks.  Patient E4 had sepsis-related hypotension 
and required inotropic support for 4 days. Neither placebo-treated patient required 
cardiovascular support. 
 
Observed versus predicted outcome 
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The mEGOS scale (Appendix 3E) was used to estimate predicted outcomes in all 
subjects. This was compared to observed outcome (Table 5). Whilst these comparative 
data are only probabilistic, subjects E4 and E5 appeared to underperform as manifested 
by the inability walk independently at week 26 despite an 85% (E4) and 93% (E5) 
probability of being able to do so, as defined by their mEGOS score. Excepting case E3 
who died, other subjects conformed to their predicted probabilities by week 26 or earlier. 
The mEGRIS scale (Appendix 3F) was used to predict requirement of mechanical 
ventilation in the first week of illness.  This was compared to observed outcome. One 
patient (E3) was predicted high risk (mEGRIS = 5) and required ventilation at day 5 of 
his illness. 
 
Discussion 
This phase 2 study was designed to assess the safety and tolerability of eculizumab 
administration concomitantly with IVIg in subjects with severe GBS (GBS DS 3 or 
greater). These data show that the combination therapy was safe and well tolerated.  
The most common AEs reported were infection and deterioration in liver function, both 
of which are recognised complications of eculizumab administration but are also 
common complications of GBS (Oomes et al., 1996).  Administering the full doses of 
eculizumab was prevented in 2 subjects due to sepsis, as outlined in the study protocol. 
This may pose a problem in severely affected subjects with GBS, as they are at a high 
risk for ventilator acquired pneumonia, aspiration due to bulbar weakness, and urinary 
tract sepsis due to indwelling urinary catheters. The effect of missed drug doses on 
attenuating systemic complement inhibition also needs to be considered, although this 
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was not formally evaluated through serum complement activity measurement in this 
study. The infusions themselves were well tolerated, with only one reported rash. The 
concomitant ciprofloxacin was also well tolerated and meningitis was not seen. The 
single fatality, occurring in an eculizumab-treated patient, was deemed to be unrelated 
to the study drug as it occurred in week 21, over 18 weeks after its last administration 
and well beyond its functional half-life. 
Recruitment into the trial was unexpectedly difficult.  Many participants declined, 
despite being eligible on other grounds.  Overwhelmingly, the perceived risk and fear of 
meningitis, a known complication of eculizumab discussed during informed consent, 
was the critical element in participants declining. Whether the excluded subjects 
introduced a selection bias is not known as their outcomes are unknown; nevertheless 
this factor should be considered. 
The small sample size means the efficacy results are not amenable to statistical 
analysis. No clear trends in efficacy were apparent but this is not unexpected in such a 
small sample size. Similarly, a small study is potentially vulnerable to differences in 
baseline characteristics that cannot be balanced in a controlled way. Larger studies 
would be required for such analysis. The overall course in these severely affected GBS 
subjects did not seem out of the ordinary, varying in range from full recovery to death. 
Neurophysiological studies and anti-ganglioside antibody analysis revealed a mixed 
cohort, with some showing markers typical for axonal GBS, and others not (Goodfellow 
and Willison 2016).  
This study concludes that eculizumab appears well tolerated in acute GBS 
subjects and can be given safely in conjunction with IVIg. Although it is tempting to 
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speculate on the varied clinical outcome following eculizumab in this group of patients 
the small sample size precludes a meaningful assessment of efficacy. Efficacy data 
from another ongoing Japanese phase 2 study of similar design (JET-GBS, 
ClinicalTrials.gov NCT02493725) are awaited with interest. The study also illustrates the 
challenges of testing novel immunotherapies in GBS subjects with sepsis. Difficulties in 
recruitment and ongoing drug administration were encountered, principally due to 
infection considerations related to both perceived risks of study drug and their frequent 
occurrence in GBS. These issues need to be carefully considered when designing 
future studies if a recruitment rate of under 30% of eligible subjects is estimated for 
phase 3 trials, study populations need to be at 3 to 4 times the recruitment target. 
Advances in treatment of GBS are urgently required, and universally adopted, 
adaptively designed trial protocols for assessing new pathway-specific immunotherapies 
that does not depend upon large randomized control trials would be advantageous for 
accelerating progress. 
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Table 1. Inclusion and exclusion criteria 
Inclusion criteria 
1. Written informed consent, or witnessed verbal informed consent 
2. Male or female ≥18 years of age. 
3. Participants diagnosed with GBS according to NINDS diagnostic criteria. 
4. Onset of weakness due to GBS within 2 weeks of enrolment.  
5. Patients who are being considered for or already on IVIg treatment. 
6. Unable to walk 10 meters independently (grade ≥ 3 on GBS disability scale). 
7. First dose of eculizumab must be started within 2 weeks from onset of weakness 
and any time during the IVIg treatment period. 
Exclusion Criteria 
1. Pregnant, lactating women or participants who wish to become pregnant during 
the study period and for 5 months following treatment completion.   
2. Participants who are being considered for or already on plasma exchange. 
3. Patient shows clear clinical evidence of a polyneuropathy caused by e.g. 
diabetes mellitus (except mild sensory), alcoholism, severe vitamin deficiency, 
and porphyria. 
4. Patient received immunosuppressive* treatment during the last month. 
5. Patient known to have a severe concurrent disease, inability to comply with study 
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CTIMP, Clinical Trial of an Investigational Medicinal Product; NINDS, National Institute 
of Neurological Disorders and Stroke; IVIG, Intravenous immunoglobulin. 
*including any dose of steroids greater than the equivalent of 20mg Prednisolone. 
 
 
 
Table 2. Study outcomes 
Primary outcomes 
1. To determine the incidence of serious adverse event/adverse events after 
treatment with eculizumab and IVIg compared to placebo control 
2. Improve one or more grade in functional outcome (GBS disability score) at 4 
weeks 
Secondary outcomes 
1. Ability to walk unaided (GBS disability score ≤ 2) at 8 weeks 
related procedures or appointments during 6 months. 
6. Any condition that in the opinion of the investigator could increase the patient’s 
risk by participating in the study or confound the outcome of the study. 
7. Enrolment in another CTIMP 6 months prior to consent 
8. Contraindications to the administration of eculizumab: 
a) Unresolved N. Meningitidis infection or history of meningococcal infection. 
b) Unsuitable for antibiotic prophylaxis, known hypersensitivity to 
eculizumab, murine proteins or to any of the excipients 
c) Known or suspected hereditary complement deficiencies. 
d) Women of child-bearing potential (WoCBP) who are unwilling to use 
effective contraception during the eculizumab treatment period and for a 
minimum of 5 months thereafter.   
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2. Time taken to improve in one grade on the GBS disability score 
3. Time taken to walk independently 
4. Difference in GBS disability score at maximum disability compared with 6 months 
5. Percentage of participants with a clinically relevant improvement  in R-ODS score 
defined as an increase from baseline  in R-ODS score by at least 6 points on the 
centile metric score at 4 weeks and 6 months 
6. Percentage of participants with a clinically relevant improvement  in ONLS 
defined as a decrease from baseline  in ONLS score by at least 1 point at 4 
weeks and 6 months 
7. Requirement for ventilatory support (GBS disability score =5) 
8. Duration of ventilatory support 
9. Recurrence of relapse 
10. Death within first 6 months 
 
GBS DS, GBS Disability Score; RODS, Rasch Overall Disability Score; ONLS, Overall 
Neuropathy Limitation Score. Baseline defined as week 0, or day 1 prior to drug 
administration. 
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Table 3. Baseline participant characteristics 
 All 
(N=8) 
Eculizumab
(N=5) 
Placebo 
(N=2) 
Gender    
Male 4  2  2  
Female 4  3  1  
Antecedent illness    
None 4 3  1 
Diarrhoea 1 1 0 
Respiratory tract infection 2 1 1 
Urinary tract infection 1 0 1 
Age (years)    
Mean (SD) 53 (16) 54 (15) 51 (20) 
Range 32 - 72 36 - 70 32 - 72 
GBS disability score*    
Bed or chair bound  (grade 4) 7 5 2 
Neurophysiology*    
Demyelinating 4 2 2 
Axonal 2 2 0 
Equivocal 1 1 0 
Anti-ganglioside antibodies* 5 4 1 
GM1 3 3 0 
GM2 2 1 1 
 
Summary of baseline characteristics for gender, antecedent illness, age, disability 
score, clinical neurophysiology results as defined by local neurophysiology department 
and autoantibodies. Data shown are number of participants, unless otherwise stated. 
* data for subject 8 who was withdrawn immediately after randomization and prior to 
treatment is not reported. 
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Table 4 Primary and Secondary Outcomes 
  All 
(N=7) 
Eculizumab 
(N=5) 
Placebo 
(N=2) 
Primary outcome     
Safety and tolerability      
Patients with adverse events  7 (100%) 5 (100%) 2 (100%) 
Total adverse events N 29 25 4 
Related to study drug Yes 9 (31%) 9 (36%) 0 (0%) 
 No 20 (69%) 16 (64%) 4 (100%) 
     
Patients with serious adverse  4 (57%) 4 (80%) 0 (0%) 
Total serious adverse events N 4 4 0 
Related to study drug Yes 1 (25%) 1 (25%) 0 (0%) 
 No 3 (75%) 3 (75%) 0 (0%) 
Death   1 (14%) 1 (20%) 0 (0%) 
Efficacy      
GBS DS improvement from week 
0 to week 4 (≥ 1) Yes 4 (57%) 2 (40%) 2 (100%) 
 No 3 (43%) 3 (60%) 0 (0%) 
Secondary Outcomes     
Independent walking  at 8 weeks Yes 2 (29%) 1(20%) 1 (50%) 
 No 5 (71%) 4(80%) 1 (50%) 
Independent walking  during trial Yes 4 (57%) 2 (40%) 2 (100%) 
 No 3 (43%) 3 (60%) 0 (0%) 
Requirement for ventilation during 
trial 
Yes 2 (29%) 2 (40%) 0 (0%) 
 No 5 (71%) 3 (60%) 2 (100%) 
Duration of ventilator support  Range 0-21 1-21 0 
 
Primary efficacy outcomes described by groups. For individual case summaries, refer to 
appendix 2.  Values given as absolute totals and percentages, unless otherwise stated. 
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Independent walking classified as GBS DS ≤ 2. Mechanical ventilation dependent 
classified as GBS DS 5
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Table 5. Observed versus predicted probability of walking 
Probability of walking independently (%; GBS DS ≤ 2), based on mEGOS classifications at weeks 4, 13 and 26, versus 
observed walking status. Walking is defined as GBS DS 2 or less. E1-E5, eculizumab-treated subjects; P1-P2 placebo-
treated subjects.  
Pred: Predicted; Obs: Observed
  
E1 
mEGOS = 4  
 
E2 
mEGOS = 6 
 
E3 
mEGOS = 11 
 
E4 
mEGOS = 7 
 
E5 
mEGOS = 5
 
P1 
mEGOS = 6 
 
P2 
mEGOS = 4 
 Pred  Obs Pred Obs Pred Obs Pred Obs Pred Obs Pred Obs Pred Obs 
4 weeks 60% No 40% No 2% No 30% No 50% No 40% Yes 60% No 
13 
weeks 
90% Yes 80% Yes 30% No 70% No 85% No 80% Yes 90% Yes 
26 
weeks 
95% Yes 90% Yes 50% No 85% No 93% No 90% Yes 95% Yes 
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Figure 1: Recruitment log for screened subjects  
Solid line denotes total GBS subjects at Hughes GBS DS grade 3 or greater undergoing screening for 
inclusion (28); dotted line denotes subjects excluded or who declined to participate (20); dashed line 
denotes subjects recruited into the study (8). The recruitment target was 30 subjects over 2 years. Of the 
20 subjects who were excluded, 12 declined to participate and 8 were excluded for failing to meet other 
inclusion criteria.  
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Figure 2: Efficacy Outcome markers plotted over time for ICA-GBS cohort  
Efficacy outcome measurements in individual subjects over time.  Panel A denotes trends in GBS disability 
scores at all trial time points (weeks 0-4, 8, 13, 26).  Panel B denotes RODS (Rasch Overall Disability Score) 
outcomes (weeks 0, 4, 8, 26).  Panel C denotes MRC sum score values per patient (weeks 0, 4, 8, 
26).  Panel D denotes ONLS (Overall Neuropathy Limitation Score) outcomes.  Solid black line = eculizumab-
treated Subjects, dashed black line = placebo-treated subjects. *In panels B-D endpoint data for E3 (who 
died at week 21) is week 13 data (not week 26).  
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